GFI named an ACE Top Charity for the fourth year in a row
Susan HaltemanGFI is honored to announce that we have been named one of the four most effective charities in the world for reducing animal suffering by Animal Charity Evaluators.
GFI is honored to announce that we have been named one of the four most effective charities in the world for reducing animal suffering by Animal Charity Evaluators.
GFI is releasing the first installment of the Plant-Based Meat Manufacturing Guide. This guide provides a practical model for producing restructured and whole muscle plant-based meat.
In order to reach cost parity with conventional meat, the cultivated meat industry will require additional participation from scientists in both industry and academia.
GFI brought entrepreneurs from across the globe on a tour of two of the most innovative new protein startups in the Bay Area: JUST and Impossible Foods.
GFI's Company Database, Investor Directory, and Industry Reports help accredited investors discover deal flow and GFI's Investor Directory helps startups connect with potential investors.
GFI, ProVeg, and 31 partner organizations across 21 countries are launching Smart Protein, a project funded by the European Commission, to develop protein-rich foods from plants, fungi, and byproducts.
GFI-India Managing Director Varun Deshpande reflects on some key takeaways and productive conversations from a whirlwind few days in sunny San Francisco at the Good Food Conference 2019.
Check out our 2019 RFP and consider whether you or someone you know should apply for up to $300,000 in research funding. The deadline for Phase 1 proposal submission is October 28, 2019.
The largest grocer in the United States just unveiled a new dedicated plant-based line under its wildly popular Simple Truth brand. The new Simple Truth Plant Based collection will debut this fall.
CPT Capital backs creative businesses that develop groundbreaking replacements for animal products. The firm supports innovators focused on plant-based protein, cell-based meat, and recombinant proteins from seed stage to sale, IPO, and longer-term.